Efficacy of Famotidine for COVID-19: A Systematic Review and Meta-analysis
Sethia, R.; Prasad, M.; Jagannath, S.; Nischal, N.; Soneja, M.; Garg, P.; Shalimar,
Show abstract
Background: Coronavirus Disease 2019 (COVID-19) pandemic continues unabated in many parts of the world. In the absence of any definite antiviral therapy except some benefit of remdesivir, there is an ongoing search for effective therapy. Famotidine has been shown to reduce mortality in hospitalized patients in a few studies. We conducted a systematic review on the use of famotidine in COVID-19. Methods: We searched the databases Medline, Embase, Cochrane CENTRAL and Medrxiv. Title/abstract screening, full text screening and data abstraction were carried out in by two reviewers. Case series, cohort studies and randomized trials were included. Results: Five studies were eligible for inclusion: all were retrospective cohort or case series. Low quality evidence suggests a likely clinical benefit for the use of famotidine in decreasing mortality in hospitalized patients with moderate to severe COVID-19. A meta-analysis of two cohort studies showed a statistically significant decrease in the composite outcome for death and intubation with famotidine (HR 0.44, 95% CI 0.27 to 0.73). Conclusion: Further evidence from RCTs is required for famotidine to treat COVID 19.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The Effect of Famotidine on Hospitalized Patients with COVID-19: a Systematic Review and Meta-analysis 95%
- Factors Associated with Disease Severity and Mortality among Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis 94%
- Colchicine use in patients with COVID-19: a systematic review and meta-analysis 94%
Similar papers in this journal
- Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis 92%
- Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews 92%
- The tryptophan catabolite or kynurenine pathway in COVID-19 and critical COVID-19: a systematic review and meta-analysis 90%
Similar papers in this journal
- A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis 92%
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 91%
- Efficacy of remdesivir in hospitalised COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan 90%
Similar papers in this journal
- Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review 92%
- Quantification of the association between predisposing health conditions, demographic, and behavioural factors with hospitalisation, intensive care unit admission, and death from COVID-19: a systematic review and meta-analysis 90%
- Direct-acting antivirals for chronic hepatitis C infection: a protocol for a systematic review of observational studies 89%
Similar papers in this journal
- Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study 92%
- Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial 90%
- Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.